Home Institutions NYU Langone Health clinical trials Institution Directory
Clinical trials at NYU Langone Health Sites in New York, NY
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:37 PM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1141
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 517–528 of 1,141 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Endometrial Adenocarcinoma
Interventions ACR-368, Gemcitabine, OncoSignature Drug · Diagnostic Test
Lead sponsor Acrivon Therapeutics Industry
Eligibility 18 Years and older · Female only
Enrollment 350 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2027
U.S. locations 69
States / cities Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
Conditions Transplant Rejection
Interventions BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids Drug
Lead sponsor Sanofi Industry
Eligibility 18 Years and older
Enrollment 48 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2026
U.S. locations 7
States / cities Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Conditions B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor Children's Oncology Group Network
Eligibility 15 Years to 40 Years
Enrollment 440 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2028
U.S. locations 225
States / cities Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
Conditions Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions Remote monitoring Behavioral
Lead sponsor University of Maryland, Baltimore Other
Eligibility 18 Years to 80 Years
Enrollment 123 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2026
U.S. locations 5
States / cities Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Conditions Drug Use, Substance Abuse, Mental Illness
Interventions Integrated Harm Reduction Intervention (IHRI) Behavioral
Lead sponsor NYU Langone Health Other
Eligibility 18 Years and older
Enrollment 200 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2028
U.S. locations 3
States / cities New Haven, Connecticut • New York, New York • Orangeburg, New York
Conditions Systemic Lupus Erythematosus
Interventions Hydroxychloroquine, Placebo Drug
Lead sponsor NYU Langone Health Other
Eligibility 55 Years and older
Enrollment 330 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2029
U.S. locations 12
States / cities Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more
Conditions Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 677 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2027
U.S. locations 41
States / cities Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Conditions New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions Anakinra, Tocilizumab, Standard medical treatment Drug · Other
Lead sponsor Yale University Other
Eligibility 2 Years and older
Enrollment 438 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2030
U.S. locations 25
States / cities Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Conditions Breast Cancer, HER2-positive Breast Cancer
Interventions trastuzumab-emtansine, Trastuzumab SC, Paclitaxel Drug
Lead sponsor Dana-Farber Cancer Institute Other
Eligibility 18 Years and older
Enrollment 500 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2021 – 2029
U.S. locations 53
States / cities San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more
Conditions Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
Interventions Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine Drug · Other
Lead sponsor Children's Oncology Group Network
Eligibility 91 Days to 3 Years
Enrollment 280 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2027
U.S. locations 169
States / cities Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
Conditions Hiatal Hernia
Interventions Biosynthetic Mesh, Hiatal Hernia Repair Device · Procedure
Lead sponsor Weill Medical College of Cornell University Other
Eligibility 18 Years and older
Enrollment 200 participants
Healthy volunteers Accepts healthy volunteers
Timeline 2024 – 2030
U.S. locations 6
States / cities Los Angeles, California • New Orleans, Louisiana • St Louis, Missouri + 1 more
Conditions Colonoscopy
Interventions Olympus colonoscope, Irrigation solution Device · Drug
Lead sponsor NYU Langone Health Other
Eligibility 45 Years to 75 Years
Enrollment 35 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2027
U.S. locations 1
States / cities New York, New York About this NYU Langone Health institution page
What this page lists ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .